{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:14:06Z","timestamp":1794014046855,"version":"4.8.0"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RRCT"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Guillain-Barre syndrome (GBS) is one of the principal causes of\nacute neuromuscular weakness and paralysis worldwide. Its clinic-epidemiological profile\nand factors influencing its treatment outcomes in developing countries are very minimally\nstudied.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The study aimed to study the risk factors, clinical presentation, management,\nand predictors of treatment outcomes among GBS patients admitted in two tertiary care\nhospitals.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p>Medical records of 121 inpatients with GBS confirmed based\non the Brighton criteria over the recent five-year period from June 2017 to May 2022 were\nexamined. Assessment of the severity of GBS was done using the Hughes functional grading\nscale.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The mean age at onset was 36.8\u00b118.9 years. The majority of the patients [82 (67.8%)]\nwere males. Antecedent illnesses within 1 month of onset of GBS were present among 34\n(28.1%) patients. The majority of them developed respiratory tract illnesses [13 (38.2%)].\nRecurrent history of GBS was observed among 4 (3.3%) patients. The median time gap between\nthe onset of antecedent illnesses and the onset of GBS was 5 days (IQR 3, 10). The most\ncommon symptom among GBS patients was the weakness of the muscles of the extremities [117\n(96.7%)]. The pattern of progression of weakness among 53 (45.3%) of these patients was from\nthe lower to upper limbs. The most common sign noted was hypotonia in 64 (52.9%) patients.\nComplications due to GBS were observed among 12 (9.9%) patients. The most common\ncomplication was respiratory distress in 11 (91.7%) patients, followed by autonomic\ndysfunctions in 8 (66.7%). Albuminocytological dissociation in cerebrospinal fluid was noted\namong 48 (39.7%) patients. The majority of patients in nerve conduction studies had\nacute inflammatory demyelinating polyneuropathy [61 (50.4%)]. The majority of the GBS\npatients [68 (56.2%)] were treated using intravenous immunoglobulin (IVIG). 95 (78.5%)\npatients improved with treatment at the time of discharge. In multivariable analysis, the absence\nof antecedent illnesses (p =0.029), Brighton\u2019s diagnostic certainty levels 1 and 2 of GBS (p\n=0.024), and being kept on IVIG treatment (p =0.05) were associated with improvement in\ndisease condition among the patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Appropriate diagnosis of GBS using both clinical and laboratory evidence and\nproviding appropriate treatment along with more supervision among GBS patients with a history\nof antecedent illnesses will help improve their prognosis at the time of discharge.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115748871254419231019053136","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T04:04:36Z","timestamp":1698811476000},"page":"258-268","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictors of Treatment Outcome and Clinical Profile among Guillain-\nBarre Syndrome Patients in South India"],"prefix":"10.2174","volume":"18","author":[{"given":"Nitin","family":"Joseph","sequence":"first","affiliation":[{"name":"Department of Community Medicine, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education,\nManipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Shrigiri","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education,\nManipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12974-021-02319-4","volume":"18","author":"Bragazzi N.L.","year":"2021","unstructured":"Bragazzi N.L.; Kolahi A.A.; Nejadghaderi S.A.; Global, regional, and national burden of Guillain\u2013Barr\u00e9 syndrome and its underlying causes from 1990 to 2019. J Neuroinflammation  2021,18(1),264","journal-title":"J Neuroinflammation"},{"key":"ref=2","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.27.20104620","author":"Gupta M.","year":"2020","unstructured":"Gupta M.; Daid S.; Etiology and Outcomes of Acute Flaccid Paralysis in Adults: A Study in Tertiary Care Center. medRxiv  2020","journal-title":"medRxiv"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/2348-3334.196059","volume":"4","author":"Mohsin N.","year":"2017","unstructured":"Mohsin N.; Asimi R.; Clinical profile of acute flaccid paralysis: A study from North India, Kashmir. CHRISMED Journal of Health and Research  2017,4(1),27-32","journal-title":"CHRISMED Journal of Health and Research"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.4103\/jfmpc.jfmpc_951_20","volume":"9","author":"Saple P.","year":"2020","unstructured":"Saple P.; Singh S.; Gupta N.; Gupta A.M.; Chandel A.S.; Waghela S.; Clinical profile and predictors for outcome in children presenting with Guillain\u2013Barr\u00e9 syndrome. J Family Med Prim Care  2020,9(10),5316-5319","journal-title":"J Family Med Prim Care"},{"key":"ref=5","year":"2018","unstructured":"National Institute of Neurological Disorders and Stroke. Guillain-Barr\u00e9 syndrome Fact Sheet: Bethesda.  Available from:  https:\/\/www.ninds.nih.gov\/guillain-barre-syndrome-fact-sheet (Accessed on: 7th October 2022).2018"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","volume":"15","author":"Leonhard S.E.","year":"2019","unstructured":"Leonhard S.E.; Mandarakas M.R.; Gondim F.A.A.; Diagnosis and management of Guillain\u2013Barr\u00e9 syndrome in ten steps. Nat Rev Neurol  2019,15(11),671-683","journal-title":"Nat Rev Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/3867946","volume":"2019","author":"Bhagat S.K.","year":"2019","unstructured":"Bhagat S.K.; Sidhant S.; Bhatta M.; Ghimire A.; Shah B.; Clinical profile, functional outcome, and mortality of guillain-barre syndrome: A five-year tertiary care experience from Nepal. Neurol Res Int  2019,2019,1-5","journal-title":"Neurol Res Int"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/brain\/awt285","volume":"137","author":"Fokke C.","year":"2014","unstructured":"Fokke C.; van den Berg B.; Drenthen J.; Walgaard C.; van Doorn P.A.; Jacobs B.C.; Diagnosis of guillain-barre syndrome and validation of brighton criteria. Brain  2014,137(1),33-43","journal-title":"Brain"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3389\/fneur.2019.00225","volume":"10","author":"Shi M.","year":"2019","unstructured":"Shi M.; Zhu J.; Deng H.; Clinical characteristics of intravenous injection of monosialotetrahexosyl ganglioside sodium-related guillain-barre syndrome. Front Neurol  2019,10,225","journal-title":"Front Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.18203\/2349-3933.ijam20162203","volume":"3","author":"Vyas A.","year":"2016","unstructured":"Vyas A.; Jaiswal K.; Swami S.; Rankawat M.; Clinical profile of adults with Guillain Barre Syndrome in North-West Rajasthan, India. International Journal of Advances in Medicine  2016,3,519-522","journal-title":"International Journal of Advances in Medicine"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.13005\/bpj\/1837","volume":"12","author":"Khairani A.F.","year":"2019","unstructured":"Khairani A.F.; Karina M.; Siswanti L.H.; Dewi M.M.; Clinical profile of pediatric guillain-barr\u00e9 syndrome: A study from National Referral Hospital in West Java, Indonesia. Biomed Pharmacol J  2019,12,2043-2048","journal-title":"Biomed Pharmacol J"},{"key":"ref=12","first-page":"Doc16","volume":"13","author":"Sudulagunta S.R.","year":"2015","unstructured":"Sudulagunta S.R.; Sodalagunta M.B.; Sepehrar M.; Guillain-Barr\u00e9 syndrome: clinical profile and management. Ger Med Sci  2015,13,Doc16","journal-title":"Ger Med Sci"},{"key":"ref=13","author":"Saravanan P.","year":"2008","unstructured":"Saravanan P.;  A study on Guillain Barre\u2019s syndrome clinical profile and treatment outcome  2008","journal-title":"A study on Guillain Barre\u2019s syndrome clinical profile and treatment outcome"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3329\/birdem.v7i1.31270","volume":"7","author":"Habib R.","year":"2017","unstructured":"Habib R.; Saifuddin M.; Islam R.; Rahman A.; Bhowmik N.B.; Haque M.A.; Clinical profile of guillain barre\u2019 syndrome-observations from a tertiary care Hospital of Bangladesh. BIRDEM Medical Journal  2017,7(1),38-42","journal-title":"BIRDEM Medical Journal"},{"key":"ref=15","first-page":"4867","volume":"9","author":"Prabhash R.","year":"2022","unstructured":"Prabhash R.; Chouksey D.; Garg R.; Clinical profile, electrophysiological findings, treatment response of Guillain Barre Syndrome: A retrospective study from tertiary care centre in Central India. EJMCM  2022,9,4867-4878","journal-title":"EJMCM"},{"key":"ref=16","first-page":"376","volume":"57","author":"Rigo D.F.H.","year":"2020","unstructured":"Rigo D.F.H.; Ross C.; Hofstatter L.M.; Ferreira M.F.A.P.L.; Guillain Barr\u00e9 syndrome: epidemiological clinical profile and nursing care. Enferm Glob  2020,57,376-389","journal-title":"Enferm Glob"},{"key":"ref=17","first-page":"38","volume":"25","author":"Kanjalkar M.M.","year":"2020","unstructured":"Kanjalkar M.M.; Sasturkar M.K.; Biradar S.B.; Clinical profile and treatment outcomes of patients of guillain-barre syndrome in tertiary care centre. IJCMAAS  2020,25,38-42","journal-title":"IJCMAAS"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.15520\/jcmro.v2i12.238","volume":"2","author":"Manju K.D.","year":"2019","unstructured":"Manju K.D.; Dogra V.D.; Singh G.; Harita. Guillain-Barre; Syndrome: Clinical Profile. Journal of Current Medical Research and Opinion  2019,2,378-382","journal-title":"Journal of Current Medical Research and Opinion"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.5455\/2320-6012.ijrms20140513","volume":"2","author":"John J.","year":"2014","unstructured":"John J.; Kannan A.; Clinical profile of Guillain Barre syndrome in a tertiary care centre. International Journal of Research in Medical Sciences  2014,2(2),445-447","journal-title":"International Journal of Research in Medical Sciences"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/0028-3886.310112","volume":"69","author":"Tullu M.S.","year":"2021","unstructured":"Tullu M.S.; Rangan R.S.; Deshmukh C.; Mondkar S.; Agrawal M.; Clinical profile and outcome of guillain\u2013barre syndrome in pediatric patients admitted to a tertiary care centre: A retrospective study. Neurol India  2021,69(1),81-84","journal-title":"Neurol India"},{"key":"ref=21","author":"Jameson J.L.","year":"2018","unstructured":"Jameson J.L.; Fauci A.S.; Kasper D.L.; Hauser S.L.; Longo D.L.; Loscalzo J.;  Harrison\u2019s Principles of Internal Medicine  2018","journal-title":"Harrison\u2019s Principles of Internal Medicine"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"22461","DOI":"10.18535\/jmscr\/v5i5.192","volume":"5","author":"Dave P.","year":"2017","unstructured":"Dave P.; Diwan A.G.; Singh B.; Thavare S.; Bonde K.; Desai B.; Study of clinical profile of Guillain Barre Syndrome. J Med Sci Clin Res  2017,5(5),22461-22466","journal-title":"J Med Sci Clin Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1212\/WNL.0b013e3181cff735","volume":"74","author":"Islam Z.","year":"2010","unstructured":"Islam Z.; Jacobs B.C.; van Belkum A.; Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology  2010,74(7),581-587","journal-title":"Neurology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ncl.2013.01.005","volume":"31","author":"Dimachkie M.M.","year":"2013","unstructured":"Dimachkie M.M.; Barohn R.J.; Guillain-Barr\u00e9 syndrome and variants. Neurol Clin  2013,31(2),491-510","journal-title":"Neurol Clin"},{"key":"ref=25","volume":"2","author":"Bradley W.G.","year":"2007","unstructured":"Bradley W.G.; Daroff R.B.; Fenichel G.M.; Jankovic J.;  Neurology in Clinical Practice  2007,2","journal-title":"Neurology in Clinical Practice"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/mus.25992","volume":"57","author":"Kalita J.","year":"2018","unstructured":"Kalita J.; Kumar M.; Misra U.K.; Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-Barr\u00e9 syndrome in India. Muscle Nerve  2018,57(5),761-765","journal-title":"Muscle Nerve"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00415-019-09634-0","volume":"267","author":"Bourque P.R.","year":"2020","unstructured":"Bourque P.R.; Brooks J.; Warman-Chardon J.; Breiner A.; Cerebrospinal fluid total protein in Guillain\u2013Barr\u00e9 syndrome variants: correlations with clinical category, severity, and electrophysiology. J Neurol  2020,267(3),746-751","journal-title":"J Neurol"},{"key":"ref=28","year":"2022","unstructured":"Infusion Associates Management. Infusion therapy treatment for Guillain-Barre Syndrome (GBS)  Available from:  https:\/\/infusionassociates.com\/infusion-therapy\/guillain-barre-syndrome\/#:~:text=IVIg%20delivers%20donor%20plasma%20to,weeks%20of%20the%20symptoms'%20onset (Accessed on: 7th October 2022).2022"},{"key":"ref=29","first-page":"CD001446","volume":"10","author":"Hughes R.A.","year":"2016","unstructured":"Hughes R.A.; Brassington R.; Gunn A.A.; van Doorn P.A.; Corticosteroids for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev  2016,10(10),CD001446","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/acn3.51627","volume":"9","author":"Papri N.","year":"2022","unstructured":"Papri N.; Doets A.Y.; Mohammad Q.D.; Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh. Ann Clin Transl Neurol  2022,9(8),1264-1275","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp-2022-329937","volume":"94","author":"Luijten L.W.G.","year":"2023","unstructured":"Luijten L.W.G.; Doets A.Y.; Arends S.; Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barr\u00e9 syndrome. J Neurol Neurosurg Psychiatry  2023,94(4),300-308","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s12098-008-0099-1","volume":"75","author":"Koul R.L.","year":"2008","unstructured":"Koul R.L.; Alfutaisi A.; Prospective study of children with Guillain-Barre syndrome. Indian J Pediatr  2008,75(8),787-790","journal-title":"Indian J Pediatr"}],"container-title":["Reviews on Recent Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748871254419231019053136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/222853\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748871254419231019053136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T13:35:21Z","timestamp":1707744921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/222853\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748871254419231019053136","relation":{},"ISSN":["1574-8871"],"issn-type":[{"value":"1574-8871","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}